Kookjeon Pharmaceutical Co., Ltd. (KOSDAQ:307750)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,195.00
+50.00 (2.33%)
At close: Aug 20, 2026

Kookjeon Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-7,849-4,2991,7364,8248,9484,038
Depreciation & Amortization
5,2505,2275,1053,1341,4441,106
Loss (Gain) From Sale of Assets
25.325.357.43-69.180
Loss (Gain) From Sale of Investments
-548.91-285.19-1,831-16.28-373.28-0.86
Loss (Gain) on Equity Investments
15.5174.0757.48-1.154.35276.83
Provision & Write-off of Bad Debts
136.941,40813.63-9.72-3.06113.92
Other Operating Activities
7,4921,882-628.322,130-9,299753.65
Change in Accounts Receivable
7,6564,107-102.16-6,493-2,128-3,916
Change in Inventory
3,2407,963-105.88-7,203-3,541-3,813
Change in Accounts Payable
-7,310-6,4665,7163,406-670.225,448
Change in Other Net Operating Assets
337.62971.15-51.68-115.82-470.41-964.89
Operating Cash Flow
8,44610,6089,967-345.45-6,0193,042
Operating Cash Flow Growth
15.09%6.44%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,919-3,114-7,867-43,923-23,285-10,409
Sale of Property, Plant & Equipment
6.276.270.73-2.09-
Cash Acquisitions
----295.92-
Divestitures
---441--
Sale (Purchase) of Intangibles
-35.95-69.83-3,622-157.99-482.07-8.8
Investment in Securities
8,696-21,77054,65218,410-53,176-22,097
Other Investing Activities
6.32360.4-228.44584.1525.3869.36
Investing Cash Flow
4,824-24,51742,796-24,314-76,633-32,579

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-10,75110,91135,734101,36327,327
Long-Term Debt Issued
--42,8278,00018,562-
Total Debt Issued
12,88210,75153,73943,734119,92527,327
Short-Term Debt Repaid
--28,920-69,335-28,338-33,395-33,653
Long-Term Debt Repaid
--9,177-845.01-1,690-933.22-293.8
Total Debt Repaid
-26,955-38,097-70,180-30,028-34,329-33,947
Net Debt Issued (Repaid)
-14,074-27,346-16,44213,70685,596-6,620
Issuance of Common Stock
1,0122,996---45,477
Repurchase of Common Stock
------1.03
Dividends Paid
--490.69-490.69--490.69-
Other Financing Activities
-408.81-3800400-5.6-0
Financing Cash Flow
-13,470-25,221-16,93214,10685,10038,856

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.850.740.69-0.26-0.340.13
Net Cash Flow
-199.18-39,13035,831-10,5542,4479,320

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
4,5277,4942,100-44,269-29,304-7,367
Free Cash Flow Growth
52.86%256.91%----
Free Cash Flow Margin
3.55%5.72%1.54%-36.29%-28.26%-8.63%
Free Cash Flow Per Share
90.09150.3042.33-902.17-571.94-167.01
Levered Free Cash Flow
-25.46-290.41-10,137-40,786-10,027-
Unlevered Free Cash Flow
2,9352,934-4,999-37,202-8,901-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1,1081,2831,7521,373771.53238.65
Cash Income Tax Paid
--93.52746.06-115.431,625518.27
Change in Working Capital
3,9246,5765,456-10,406-6,809-3,245